Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
Status:
Completed
Trial end date:
2015-12-31
Target enrollment:
Participant gender:
Summary
This pilot phase I trial studies how well dasatinib works together with paclitaxel and
carboplatin in treating patients with stage III, stage IV, or endometrial cancer that has
come back after a period of improvement. Dasatinib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Giving dasatinib together with paclitaxel and carboplatin may kill more tumor cells.